Cilta-cel was evaluated in the CARTITUDE-1 trial (NCT03548207) in patients with R/R MM with disease refractory to at least four prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and a CD38 monoclonal antibody as part of the four or more lines.15 Here, CD38 is linked to Miyoshi myopathy.